MicroRNA expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of microRNAs

Oncology Reports

Volumn 26, Issue 4, 2011, Pages 995-1002

  Devor, Eric J ^a   Hovey, Adriann M ^a   Goodheart, Michael J ^a,b   Ramachandran, Shyam ^a   Leslie, Kimberly K ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Endometrial cancer; Endometrioid adenocarcinoma; MicroRNA; Serous adenocarcinoma

Indexed keywords

MICRORNA; MICRORNA 1; MICRORNA 125B 2; MICRORNA 129 3P; MICRORNA 133A; MICRORNA 133B; MICRORNA 135A; MICRORNA 135B; MICRORNA 137; MICRORNA 141; MICRORNA 142 3P; MICRORNA 142 5P; MICRORNA 15B; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 205; MICRORNA 429; MICRORNA 504; MICRORNA 519A; MICRORNA 888; RNA; UNCLASSIFIED DRUG; WNT PROTEIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RNA EXTRACTION; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION;

AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; CELL DIFFERENTIATION; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MIDDLE AGED; POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 79960811188     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1372     Document Type: Article

References (53)

1. Jemal A, Siegal R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007. (Pubitemid 46148091)
2. Pecorelli S, Pasinetti B, Angioli R, Favalli G and Odicino F: Systematic therapy for gynecological neoplasms ovary, cervix, and endometrium. Cancer Chemother Bio Response Modif 22: 515-544, 2005.
3. Boren T, Xiong Y, Hakam A, et al: MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecol Oncol 110: 206-215, 2008.
4. Chung TK, Cheung TH, Huen NY, et al: Dysregulated microRNAs and their predicted targets associated with endometrioid endometrialadenocarcinoma in Hong Kong women. Int J Cancer 124: 1358-1365, 2009.
5. Wu W, Lin Z, Zhuang Z and Liang X: Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. Eur J Cancer Prev 18: 50-55, 2009.
6. Hiroki E, Akahira JI, Suzuki F, Nagase S, Ito K, Sasano H and Yaegashi N: Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci 101: 241-249, 2010.
7. Ratner ES, Tuck D, Richter C, et al: MicroRNA signatures differentiate uterine cancer tumor subtypes. Gynecol Oncol 118: 251-257, 2010.
8. Volinia S, Galasso M, Costinean S, et al: Reprogramming of miRNA networks in cancer and leukemia. Genome Res 20: 589-599, 2010.
9. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2[-delta delta C(T)] method. Methods 25: 402-408, 2001. (Pubitemid 34164012)
10. Allison DB, Cui X, Page GP and Sabripour M: Microarray data analysis from disarray to consolidation and consensus. Nat Rev Genet 7: 55-65, 2006. (Pubitemid 41828948)
11. Risinger JI, Maxwell GL, Chandramouli GV, et al: Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res 63: 6-11, 2003. (Pubitemid 36070410)
12. Smid-Koopman E, Blok LJ, Chadha-Ajwani S, Helmerhorst TJ, Brinkmann AO and Huikeshoven FJ: Gene expression profiles of human endometrial cancer samples using a cDNA-expression array technique: assessment of an analysis method. Br J Cancer 83: 246-251, 2000. (Pubitemid 30411725)
13. Davalos V and Esteller M: MicroRNAs and cancer epigenetics a macrorevolution. Curr Opin Oncol 22: 35-45, 2010.
14. Garofalo M, Condorelli GL, Croce CM and Condorelli G: microRNAs as regulators of death receptor signaling. Cell Death Differ 17: 200-208, 2010.
15. Spizzo R, Nicoloso MS, Croce CM and Calin GA: SnapShot: microRNAs in cancer. Cell 137: 586.e1, 2009.
16. Lee E-K, Han GY, Park HW, Song YJ and Kim CW: Transgelin promotes migration and invasion of cancer stem cells. J Proteome Res 9: 5108-5117, 2010.
17. Kulshreshtha R, Ferracin M, Wojcik SE, et al: A microRNA signature of hypoxia. Mol Cell Biol 27: 1859-1867, 2007.
18. Vrba L, Jensen TJ, Garbe JC, et al: Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS One 5: e8697, 2010.
19. Gregory P, Bert A, Paterson E, et al: The miR-200 family and miR-205 regulate epithelial to msenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10: 593-601, 2008. (Pubitemid 351627379)
20. Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK and Richer JK: MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 8: 1055-1066, 2009.
21. Segura M, Hanniford D, Menendez S, et al: Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalimia-associated transcription factor. Proc Natl Acad Sci USA 106: 1814-1819, 2009.
22. Vaksman O, Stavnes HT, Kærn J, Trope CG, Davidson B and Reich R: miRNA profiling along tumor progression in ovarian carcinoma. J Cell Mol Med: Aug 16, 2010 (Epub ahead of print).
23. Myatt SS, Wang J, Monteiro LJ, et al: Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res 70: 367-377, 2010.
24. Guttilla IK and White BA: Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem 284: 23204-23216, 2009.
25. Greither T, Grochola LF, Udelnow A, Lautenschlager C, Wurl P and Taubert H: Elevated expression of microRNAs 155, 203, 210, and 222 in pancreatic tumors associated with poorer survival. Int J Cancer 126: 73-80, 2010.
26. Iorio MV, Visone R, Di Leva G, et al: MicroRNA signatures in human ovarian cancer. Cancer Res 67: 8699-8707, 2007. (Pubitemid 47437445)
27. Maldonado L and Hoque MO: Epigenomics and ovarian cancer. Biomark Med 4: 543-570, 2010.
28. Zhang L, Volinia S, Bonome T, et al: Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA 105: 7004-7009, 2008. (Pubitemid 351754520)
29. Huang YW, Liu JC, Deatherage DE, et al: Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res 69: 9038-9046, 2009.
30. Tiapale J and Beachy PA: The hedgehog and Wnt signaling pathways in cancer. Nature 411: 349-354, 2001.
31. Logan CY and Nusse R: The Wnt signaling pathway in development and disease. Ann Rev Cell Dev Biol 20: 781-810, 2004. (Pubitemid 39488658)
32. Powell SM, Zilz N, Beazer-Barclay Y, et al: APC mutations occur early during colorectal tumorigenesis. Nature 359: 235-237, 1992.
33. Clevers H: Wnt/β-catenin signaling in development and disease. Cell 127: 469-480, 2006.
34. Sansom OJ, Reed KR, Hayes AJ, et al: Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation and migration. Genes Dev 18: 1385-1390, 2004. (Pubitemid 38780625)
35. Nagel R, Le Sage C, Diosdado B, et al: Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res 68: 5795-5802, 2008.
36. Bui TV and Mendell JT: Myc: maestro of microRNAs. Genes Cancer 1: 568-575, 2010.
37. Li J, Liu Y, Dong D and Zhang Z: Evolution of an X-linked primate-specific microRNA cluster. Mol Biol Evol 27: 671-683, 2010.
38. Kumar NS, Richer J, Owen G, Litman E, Horwitz KB and Leslie KK: Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells implication for unopposed estrogen action. Cancer Res 58: 1860-1865, 1998. (Pubitemid 28217459)
39. Leslie KK, Stein MP, Kumar NS, et al: Progesterone receptor isoform identification and subcellular localization in endometrial cancer. Gynecol Oncol 96: 32-41, 2005. (Pubitemid 39612414)
40. Jongen V, Briët J, De Jong R, et al: Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol 112: 537-542, 2009.
41. Kim JJ and Chapman-Davis E: Role of progesterone in endometrial cancer. Sem Reprod Med 28: 81-90, 2010.
42. Cai X and Cullen BR: The imprinted H19 non-coding RNA is a primary microRNA precursor. RNA 13: 313-316, 2007. (Pubitemid 46327534)
43. Smits G, Mungall AJ, Griffiths-Jones S, et al: Conservation of the H19 non-coding RNA and H19-IGF2 imprinting mechanism in therians. Nat Genet 40: 971-976, 2008.
44. Tanos V, Prus D, Ayesh S, et al: Expression of the imprinted H19 oncofetal RNA in epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 85: 7-11, 1999. (Pubitemid 29248776)
45. Cui H, Onyango P, Brandenburg S, Wu Y, Hsieh CL and Feinberg AP: Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res 62: 6442-6446, 2002. (Pubitemid 35364103)
46. Ariel I, Miao HQ, Ji XR, et al: Imprinted H19 oncofetal RNA is a candidate marker for hepatocellular carcinoma. Mol Pathol 51: 21-25, 1998. (Pubitemid 28157352)
47. Verkerk AJ, Ariel I, Dekker MC, et al: Unique expression patterns of H19 in human testicular cancers of different etiology. Oncogene 14: 95-107, 1997. (Pubitemid 27042959)
48. Hibi K, Nakamura H, Hirai A, et al: Loss of H19 imprinting in esophageal cancer. Cancer Res 56: 480-482, 1996. (Pubitemid 26048601)
49. Byun HM, Wong HL, Birnstein EA, Wolff EM, Liang G and Yang AS: Examination of IGF2 and H19 loss of imprinting in bladder cancer. Cancer Res 67: 10753-10758, 2007. (Pubitemid 350145902)
50. Lottin S, Adriaenssens E, Berteaux N, et al: The human H19 gene is frequently overexpressed in myometrium and stroma during pathological endometrial proliferative events. Eur J Cancer 41: 168-177, 2005. (Pubitemid 40029670)
51. Tsang WP, Ng EK, Ng SSM, Jin H, Yu J, Sung JJY and Kwok TT: Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis 31: 350-358, 2010.
52. Dugimont T, Montpellier C, Adriaenssens E, et al: The H19 TATA-les promoter is efficiently repressed by wild-type tumor suppressor gene product p53. Oncogene 16: 2395-2401, 1998. (Pubitemid 28226887)
53. Adriaenssens E, Lottin S, Dugimont T, et al: Steroid hormones modulate H19 gene expression in both mammary gland and uterus. Oncogene 18: 4460-4473, 1999. (Pubitemid 29396654)